Speclipse has developed a transformative, patented technology for real-time, non-invasive, in-vivo skin cancer diagnosis using laser spectroscopy and deep learning algorithms.
We are continually improving products to make it easier to use, so physicians can focus on their patients and make accurate diagnoses, instead of their devices. We are committed to providing innovative medical technology to assist in challenging diagnosis cases.
CEO / Speclipse, Inc.
Speclipse, Inc., a medical device company founded by Stanford University graduates and a dermatologist, offers the world first cancer diagnostic solution based on Laser-Induced Plasma Spectroscopy (LIPS) and Artificial Intelligence (AI) Technology. Its core technology, Spectra-Scope®, embodies a new solution to the diagnosis of skin cancers without compromising efficacy and accuracy, therefore preventing unnecessary biopsy.
Spectra-Scope® Stand Alone received CE MDD and Australia TGA
Spectra-Scope® Add-on received CE MDD and Australia TGA
Selected as among the TOP 10 Dermatology Solution Providers by Medtech Outlook, U.S.
Speclipse, US. Established in Sunnyvale, CA
Speclipse Australia Pty Ltd., Established in Erskineville, NSW
Attracted $2.6 million in venture capitals including support from Softbank Ventures
Spectra-Scope® Add-on was developed, and clinical test started in the U.S. and Australia